Genentech Initiates Phase III Trial of Rituximab in Pemphigus Vulgaris

August 25, 2015

Genentech has initiated a Phase III clinical trial investigating the use of Rituxan (rituximab) in patients with pemphigus vulgaris (PV). The aim of the PEMPHIX study is to determine the efficacy and safety of Rituxan for the treatment of PV. 

According to the company, results of independent studies have shown that Rituxan may provide substantial improvement in PV remission rates and successful tapering and/or cessation of corticosteroid (CS) therapy. If approved, Rituxan could be the first FDA-approved biologic treatment for this autoimmune disorder that impacts approximately 30,000 people in the U.S. Rituxan for PV has also been granted orphan drug designation by the FDA.

PEMPHIX (NCT02383589) is a Phase III, randomized, double-blind, double-dummy, active-comparator, multicenter, international study to evaluate the efficacy and safety of Rituxan compared to mycophenolate mofetil in patients with moderate-to-severely active pemphigus vulgaris (PV). Patients in the Rituxan arm of the study will receive 1000mg rituximab given by intravenous infusion on Day 1 and 15, with repeat rituximab administration on Day 168 and 182 provided specific safety criteria have been met.

“We are taking the knowledge gained from the efficacy demonstrated by Rituxan in B cell-mediated autoimmune diseases such as rheumatoid arthritis and ANCA-associated vasculitis and applying it to research for pemphigus vulgaris,” said Paul Brunetta, MD, associate group medical director, Genentech Immunology. “The ongoing investigation of Rituxan for the treatment of pemphigus vulgaris demonstrates Genentech’s commitment to follow the science and address the unmet medical needs of patients.”

“Current treatments for pemphigus vulgaris can cause significant, long-term side effects,” said Victoria P. Werth, MD, Professor of Dermatology and Medicine at the University of Pennsylvania and lead investigator for the PEMPHIX trial. “It is our hope that the PEMPHIX trial will demonstrate the efficacy and safety of Rituxan for this disease and provide patients with a much-needed, FDA-approved treatment option.”

Rituxan is currently approved for the autoimmune disorders rheumatoid arthritis, granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA).

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free